APR 15, 2016 12:06 PM PDT

Algorithm Predicts If Treatment Could Help Liver Disease Patient

WRITTEN BY: Julianne Chiaet
Researchers have designed an algorithm to help physicians make decisions on whether they should treat a patient suffering from End-Stage Liver Disease (ESLD). If the patient is most likely to die, and recommending intensive care treatment won’t benefit them, the physician should not recommend the treatment. 

The algorithm, presented today at The International Liver Congress in Barcelona, gives a more accurate prediction on who is likely to benefit from treatment compared to previous measures, said hepatologist Katrine Landvig, the lead study author and a PhD fellow at the University of Copenhagen. The formula was able to successfully predict death in 96 percent of ESLD patients and is based on a combination of scales used to assess the severity of diseases, including Child-Pugh Score, Model for ESLD, and the CLIF-SOFA score. 

Acute-on-chronic liver failure is a relatively common syndrome that occurs in 31 percent of patients hospitalized for an acute complication of cirrhosis who also have organ failure and are at high risk of short-term death. Patients suffering from acute-on-chronic liver failure are usually younger and have more scarring in the liver due to alcohol (as opposed to the scarring caused by Hepatitis C in patients with decompensated cirrhosis).
 

In order to test the algorithm, researchers looked at the data of 354 hospitalized patients suffering from cirrhosis. The patients were hospitalized in Belgium, Austria, and Denmark. The algorithm separated the patients into two groups: a group likely to benefit and survive ICU and a group who were not likely to benefit or survive ICU. 

"If the first duty of a physician is to do no harm, then we must continually review our decision-making tools and favor those that have the highest predictive value of treatment success," said EASL Vice-Secretary Tom Hemming Karlsen. “This study adds to our knowledge of existing, well-recognized scoring systems, and provides an interesting approach for review and wider discussion by the liver community.” 

Sources: European Association for the Study of the Liver press release via EurekAlert!, “Acute-on-chronic Liver Failure” via Medscape 
About the Author
  • Julianne (@JuliChiaet) covers health and medicine for LabRoots. Her work has been published in The Daily Beast, Scientific American, and MailOnline. While primarily a science journalist, she has also covered culture and Japanese organized crime. She is the New York Board Representative for the Asian American Journalists Association (AAJA). • To read more of her writing, or to send her a message, go to Jchiaet.com
You May Also Like
APR 22, 2020
Drug Discovery & Development
APR 22, 2020
Only 3% of COVID-19 Antibody Tests Approved by FDA
So far, only 3% of at least 90 COVID-19 antibody tests in the US have been approved by the Food and Drug Administration ...
APR 22, 2020
Cardiology
APR 22, 2020
COVID-19 Connected to an Increase Occurrence of Blood Clots
COVID-19 linked to cardiac issues  
APR 23, 2020
Clinical & Molecular DX
APR 23, 2020
FDA Approves At-Home Sample Collection Diagnostic Test for COVID-19
The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). M ...
APR 30, 2020
Cancer
APR 30, 2020
A New microRNA for the Cancer Fighting Toolkit
MiRNAs are small snippets of genetic information that regulate gene expression thought to be able to regulate up to 60% ...
MAY 04, 2020
Cardiology
MAY 04, 2020
Machine Learning May Help in the Diagnosis of Inherited High Cholesterol
Familial hypercholesterolemia, or FH, is an inherited genetic mutation in how the body recycles LDL cholesterol (bad cho ...
MAY 12, 2020
Clinical & Molecular DX
MAY 12, 2020
Could Catching the Flu Be Linked to an Increased Cancer Risk?
Results from a new research study suggest that a spike in infections such as influenza could be linked to the risk of de ...
Loading Comments...